

## Zeniplitin

## Chemical Properties


CAS No. : 111490-36-9

Formula: C<sub>11</sub>H<sub>20</sub>N<sub>2</sub>O<sub>6</sub>Pt

Molecular Weight: 471.36

Storage:

Keep away from direct sunlight, The compound is unstable in solution. Please use soon  
 Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
 Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Zeniplitin (Zeniplitinum) is a new cisplatin complex with anticancer activity for the treatment of metastatic melanoma and kidney cancer.
Targets(IC50)	Others

## Solubility Information

Solubility	DMSO: 55 mg/mL (116.68 mM), Sonication is recommended. DMSO inactivates the activity of Zeniplitin. ( < 1 mg/ml refers to the product slightly soluble or insoluble)
------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1215 mL	10.6076 mL	21.2152 mL
5 mM	0.4243 mL	2.1215 mL	4.243 mL
10 mM	0.2122 mL	1.0608 mL	2.1215 mL
50 mM	0.0424 mL	0.2122 mL	0.4243 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

- Aamdal S, Brunsch U, Kerger J, Verweij J, ten Bokkel Huinink W, Wanders J, Rastogi R, Franklin HR, Kaye SB. Zeniplitin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity. *Cancer Chemother Pharmacol.* 1997;40(5):439-43. PubMed PMID: 9272122.
- Olver I, Green M, Peters W, Zimet A, Toner G, Bishop J, Ketelbey W, Rastogi R, Birkhofer M. A phase II trial of zeniplatin in metastatic melanoma. *Am J Clin Oncol.* 1995 Feb;18(1):56-8. PubMed PMID: 7847260.
- DeMarco LC, Budman DR, Lathia C, Amorusi P, Birkhofer M, Lichtman S, Weiselberg L, Vinciguerra V, Lovecchio J, Gal D, et al. Pharmacokinetic evaluation of zeniplatin in humans. *Cancer Chemother Pharmacol.* 1995;36(1):35-40. PubMed PMID: 7720173.
- Sorensen JB. Treatment of non-small cell lung cancer: new cytostatic agents. *Lung Cancer.* 1993 Dec;10(3-4):173-87. Review. PubMed PMID: 8075965.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481